These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29564490)

  • 1. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.
    Ceccon G; Lazaridis L; Stoffels G; Rapp M; Weber M; Blau T; Lohmann P; Kebir S; Herrmann K; Fink GR; Langen KJ; Glas M; Galldiks N
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1626-1635. PubMed ID: 29564490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
    Bashir A; Brennum J; Broholm H; Law I
    J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
    Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
    Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
    Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
    Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
    J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
    Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
    J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
    Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI.
    Werner JM; Stoffels G; Lichtenstein T; Borggrefe J; Lohmann P; Ceccon G; Shah NJ; Fink GR; Langen KJ; Kabbasch C; Galldiks N
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1889-1901. PubMed ID: 31203420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Suchorska B; Unterrainer M; Biczok A; Sosnova M; Forbrig R; Bartenstein P; Tonn JC; Albert NL; Kreth FW
    J Neurooncol; 2018 Sep; 139(3):721-730. PubMed ID: 29948765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
    Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
    J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
    Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.
    Lohmann P; Stavrinou P; Lipke K; Bauer EK; Ceccon G; Werner JM; Neumaier B; Fink GR; Shah NJ; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):591-602. PubMed ID: 30327856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of Dynamic O-(2-[
    Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
    World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.